Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Yiling Pharma Climbs in Post-IPO Trading

publication date: Jul 28, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shares of Shijiazhuang Yiling Pharmaceutical climbed 27% following the company’s IPO on the ChiNext exchange. As we reported last week, the company, which makes cardiovascular and cerebrovascular medicines, bumped the price of its IPO higher by one-third due to higher-than-expected demand, raising the value of the transaction to 2.25 billion RMB ($348 million). Even after the price increase, investors still bid the shares up when they began trading. More details....

Stock Symbol: (SHE: 002603)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors